SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 17th, 2017 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of April 6, 2017, is by and among Amarantus Bioscience Holdings, Inc., a Nevada corporation with offices located at 655 Montgomery Street, Suite 900, San Francisco, CA 9411 (the “Company”), and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).
AMENDMENT NO. 1 TO PLEDGE AGREEMENTPledge Agreement • April 17th, 2017 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 ( this “Amendment”), dated April 6, 2017, to the PLEDGE AGREEMENT, dated as of October 25, 2016 (the “Agreement”) between Amarantus Biosciences Holdings, Inc. (“Borrower”) and Xpress Group International Limited (“Xpress”) and Dominick Membership, LLC (“Dominick” and together with Xpress, “Purchasers” and each, a “Purchaser”) for the benefit of Purchasers, it being understood that subject to the terms of the First Purchase Agreement (as defined below), any right, remedy, privilege or power of Purchasers shall be exercised by each Purchaser together or individually.
SECOND AMENDMENT TO INTERCREDITOR AND SUBORDINATION GREEMENTIntercreditor and Subordination Greement • April 17th, 2017 • Amarantus Bioscience Holdings, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO INTERCREDITOR AND SUBORDINATION AGREEMENT (“Second Amendment”), dated as of April 6, 2017, by and among the holders of the Company’s Series E Preferred Stock (the “Series E Holders”) and the holders of the Company’s Series H Preferred Stock (“Series H Holders”), Amarantus Bioscience Holdings, Inc. (the “Company”), all of the subsidiaries of the Company (such subsidiaries, the “Subsidiaries”, the Company jointly and severally, together with their respective successors and assigns, collectively, the “Debtors”), GEMG LLC (“GEMG”), ANSON INVESTMENTS MASTER FUND LP (“Anson”), DOMINION CAPITAL, LLC, (“Dominion”) and DELAFIELD INVESTMENTS LIMITED (“Delafield”) the holders (collectively, the “April 2016 Holders”) of the Company’s 12% OID Senior Secured Convertible Promissory Notes, in the original aggregate principal amount of $9,125,000 pursuant to the Senior Loan Agreement, Delafield in its capacity as collateral agent (in such capacity, the “Collateral Agent”) and D
